Registre Français de la maladie de Pompe. Caractérisation d’une cohorte de 126 patients adultes
P. Laforêt, K. Laloui, B. Granger, D. Hamroun, N. Taouagh, JY. Hogrel, D. Orlikowski, F. Bouhour, A. Lacour, E. Salort-Campana, I. Penisson-Besnier, S. Sacconi, F. Zagnoli, F. Chapon, B. Eymard, C. Desnuelle, J. Pouget et le French Pompe Registry Study Group
Revue neurologique. 2013. 169:595-602.
The French Pompe registry was created in 2004 with the initial aim of studying the natural history of French patients with adult Pompe disease. Since the marketing in 2006 of enzyme replacement therapy (alglucosidase alfa, Myozyme1), the French Pompe registry has also been used to prospectively gather the biological and clinical follow-up data of all adult patients currently treated in France.
This report describes the main clinical and molecular features, at the time of inclusion in the French registry, of 126 patients followed up in 21 hospital-based neuromuscular or metabolic centers. The MFM, which has been used to evaluate the level of impairment of muscle function, appears to be a useful tool, particularly with regard to the D1 domain. Good correlations between MFM scores and 6MWT confirmed the importance of the MFM measurement in the follow-up of patients with Pompe disease.
Keywords: Pompe disease, Pompe registry, Acid alpha-glucosidase deficiency
Articles in scientific journals
Création et validation d’une classification en grade de sévérité dans les maladies neuromusculaires : la classification NM-Score
Vuillerot C, Rippert P, Roche S, Bérard C, Margirier F, de Lattre C, Poirot I, Berruyer A, Tiffreau V, Fournier-Mehouas M, Bouhour F, Urtizberea JA, Renders A, Ecochard R; Le groupe d’étude NM-Score. Ann Phys Rehabil Med. 2013. 56(9-10):673-86. Development of a...
Rasch analysis of clinical outcome measures in spinal muscular atrophy
SJ. Cano, A. Mayhew, AM. Glanzman, KJ. Krosschell, KJ. Swoboda, M. Main, BF. Steffensen, C. Bérard, F. Girardot, CA. Payan, E. Mercuri, E. Mazzone, B. Elsheikh, J. Florence, LS. Hynan, ST. Iannaccone , LL. Nelson, S. Pandya, M. Rose, C. Scott, R. Sadjadi, MA. Yore, C....
Gait energy expenditure in children with Duchenne muscular dystrophy: case study
de Souza MA, Ferreira ME, Rogean de Jesus Alves de Baptista C, Mattiello Sverzut AC. Fisioter Pesq. 2014. 21(2):193-198. Energy expenditure of 3 children (6, 7 and 8 years old) with MFM scores between 61.5 and 71.7% was calculated using gait heart rate (HR).Results...
Physiotherapy Intervention in Nemaline Myopathy – Case Report
Furlaneto B, Valenciano P, Zechim F, Alves E. Revista Neurociências. 2014. 22(1):59-65. This report provides an understanding of the clinical evolution and prognosis of a Nemaline Myopathy (NM) patient compared with the literature.Physiotherapeutic interventions were...
Activity rating scales in adult muscle disease: how well do they actually measure?
Seedat F, James MK, Rose MR. Muscle Nerve. 2014. 50(1):24-33. Systematic review to assess the quality of 19 activity rating scales, including the MFM, designed specifically for muscle disease.PubMed linkKeywords: Functional rating scales, Muscle disease, Outcome...
Activity rating scales in adult muscle disease: what do they actually measure?
Seedat F, James MK, Rose MR. Muscle Nerve. 2014. 50(1):14-23. Literature review of activity rating scales used for muscle disease and assessed their content by linking scale items to the International Classification of Functioning, Disability and Health (ICF) and the...